Idenix Pharmaceuticals Inc (IDIX), Bristol Myers Squibb Co. (BMY): The Most Unlucky Biotech in the World

Page 2 of 2

And by the time IDX20963 gets approved, there will be perhaps a dozen drugs approved to treat hepatitis C. I can’t imagine entering the market at that point is going to be easy, and any delays in development will only make it harder.

Idenix still has one more compound, IDX719, in phase 2 development, so the company isn’t entirely dead. It might even get acquired by Johnson & Johnson (NYSE:JNJ), which is testing its hepatitis C drugs in combination with IDX719, if the combinations looks good.

Assuming, of course, that Idenix’s string of bad luck doesn’t extend to IDX719.

The article The Most Unlucky Biotech in the World originally appeared on Fool.com is written by Brian Orelli.

Fool contributor Brian Orelli has no position in any stocks mentioned. The Motley Fool recommends Gilead Sciences and Johnson & Johnson. The Motley Fool owns shares of Johnson & Johnson.

Copyright © 1995 – 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

Page 2 of 2